ARTIVION INC (AORT) Stock Fundamental Analysis
USA - NYSE:AORT - US2289031005 - Common Stock
42.3 USD
-0.31 (-0.73%)
42.3 USD
0 (0%)
AORT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. AORT has only an average score on both its financial health and profitability. AORT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
AORT had negative earnings in the past year.
AORT had a positive operating cash flow in the past year.
AORT had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: AORT reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of AORT (-2.13%) is better than 68.95% of its industry peers.
Looking at the Return On Equity, with a value of -4.26%, AORT is in the better half of the industry, outperforming 68.95% of the companies in the same industry.
AORT has a better Return On Invested Capital (2.15%) than 69.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.13% | ||
| ROE | -4.26% | ||
| ROIC | 2.15% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AORT's Operating Margin of 5.18% is fine compared to the rest of the industry. AORT outperforms 70.00% of its industry peers.
In the last couple of years the Operating Margin of AORT has grown nicely.
AORT's Gross Margin of 63.99% is fine compared to the rest of the industry. AORT outperforms 66.84% of its industry peers.
AORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.18% | ||
| PM (TTM) | N/A | ||
| GM | 63.99% |
OM growth 3Y34.21%
OM growth 5Y6.88%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
AORT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
AORT has more shares outstanding than it did 1 year ago.
AORT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AORT is higher compared to a year ago.
2.2 Solvency
AORT has an Altman-Z score of 3.69. This indicates that AORT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.69, AORT is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
AORT has a debt to FCF ratio of 28.63. This is a negative value and a sign of low solvency as AORT would need 28.63 years to pay back of all of its debts.
AORT has a Debt to FCF ratio of 28.63. This is in the better half of the industry: AORT outperforms 68.95% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that AORT is somewhat dependend on debt financing.
The Debt to Equity ratio of AORT (0.52) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 28.63 | ||
| Altman-Z | 3.69 |
ROIC/WACC0.26
WACC8.3%
2.3 Liquidity
A Current Ratio of 4.78 indicates that AORT has no problem at all paying its short term obligations.
AORT's Current ratio of 4.78 is fine compared to the rest of the industry. AORT outperforms 76.32% of its industry peers.
A Quick Ratio of 3.48 indicates that AORT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.48, AORT is doing good in the industry, outperforming 71.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
The earnings per share for AORT have decreased strongly by -12.12% in the last year.
The Revenue has been growing slightly by 7.44% in the past year.
Measured over the past years, AORT shows a small growth in Revenue. The Revenue has been growing by 7.06% on average per year.
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%260%
Revenue 1Y (TTM)7.44%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%15.26%
3.2 Future
AORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.79% yearly.
The Revenue is expected to grow by 11.19% on average over the next years. This is quite good.
EPS Next Y126.5%
EPS Next 2Y71.78%
EPS Next 3Y50.72%
EPS Next 5Y46.79%
Revenue Next Year11.74%
Revenue Next 2Y11.27%
Revenue Next 3Y11.48%
Revenue Next 5Y11.19%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AORT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 103.45, which means the current valuation is very expensive for AORT.
Based on the Price/Forward Earnings ratio, AORT is valued a bit cheaper than the industry average as 67.37% of the companies are valued more expensively.
AORT is valuated expensively when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 103.45 |
4.2 Price Multiples
66.84% of the companies in the same industry are more expensive than AORT, based on the Enterprise Value to EBITDA ratio.
66.84% of the companies in the same industry are more expensive than AORT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 260.43 | ||
| EV/EBITDA | 48.71 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AORT's earnings are expected to grow with 50.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y71.78%
EPS Next 3Y50.72%
5. Dividend
5.1 Amount
AORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
42.3
-0.31 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners84.01%
Inst Owner ChangeN/A
Ins Owners4.41%
Ins Owner Change-1.55%
Market Cap2.00B
Analysts83.08
Price Target44.56 (5.34%)
Short Float %2.57%
Short Ratio2.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1009.98%
Min EPS beat(2)91.71%
Max EPS beat(2)1928.24%
EPS beat(4)3
Avg EPS beat(4)376.32%
Min EPS beat(4)-537.25%
Max EPS beat(4)1928.24%
EPS beat(8)5
Avg EPS beat(8)158.13%
EPS beat(12)8
Avg EPS beat(12)112.3%
EPS beat(16)10
Avg EPS beat(16)39.11%
Revenue beat(2)2
Avg Revenue beat(2)2.37%
Min Revenue beat(2)2.16%
Max Revenue beat(2)2.59%
Revenue beat(4)2
Avg Revenue beat(4)-0.38%
Min Revenue beat(4)-5.37%
Max Revenue beat(4)2.59%
Revenue beat(8)5
Avg Revenue beat(8)0.72%
Revenue beat(12)7
Avg Revenue beat(12)0.63%
Revenue beat(16)10
Avg Revenue beat(16)0.53%
PT rev (1m)3.03%
PT rev (3m)33.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-36.85%
EPS NY rev (1m)-1.26%
EPS NY rev (3m)1.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 103.45 | ||
| P/S | 4.93 | ||
| P/FCF | 260.43 | ||
| P/OCF | 101.55 | ||
| P/B | 4.75 | ||
| P/tB | 260.54 | ||
| EV/EBITDA | 48.71 |
EPS(TTM)-0.37
EYN/A
EPS(NY)0.41
Fwd EY0.97%
FCF(TTM)0.16
FCFY0.38%
OCF(TTM)0.42
OCFY0.98%
SpS8.58
BVpS8.9
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.13% | ||
| ROE | -4.26% | ||
| ROCE | 2.72% | ||
| ROIC | 2.15% | ||
| ROICexc | 2.31% | ||
| ROICexgc | 5.42% | ||
| OM | 5.18% | ||
| PM (TTM) | N/A | ||
| GM | 63.99% | ||
| FCFM | 1.89% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y40.9%
ROICexcg growth 5Y5.66%
ROICexc growth 3Y48.24%
ROICexc growth 5Y9.09%
OM growth 3Y34.21%
OM growth 5Y6.88%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 28.63 | ||
| Debt/EBITDA | 4.93 | ||
| Cap/Depr | 51.26% | ||
| Cap/Sales | 2.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 44.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 3.69 |
F-Score4
WACC8.3%
ROIC/WACC0.26
Cap/Depr(3y)42.06%
Cap/Depr(5y)43.23%
Cap/Sales(3y)2.8%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%260%
EPS Next Y126.5%
EPS Next 2Y71.78%
EPS Next 3Y50.72%
EPS Next 5Y46.79%
Revenue 1Y (TTM)7.44%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%15.26%
Revenue Next Year11.74%
Revenue Next 2Y11.27%
Revenue Next 3Y11.48%
Revenue Next 5Y11.19%
EBIT growth 1Y-22.98%
EBIT growth 3Y46.49%
EBIT growth 5Y14.43%
EBIT Next Year112.29%
EBIT Next 3Y43.08%
EBIT Next 5Y32.16%
FCF growth 1Y224.1%
FCF growth 3YN/A
FCF growth 5Y7.33%
OCF growth 1Y335.36%
OCF growth 3YN/A
OCF growth 5Y7.04%